Comparison of live and inactivated influenza vaccine in high risk children

Area of Science:

• Immunology
• Vaccinology
• Pediatrics

Background:

• Influenza A poses a significant risk to individuals with cystic fibrosis.
• Evaluating different influenza vaccine types is crucial for optimizing protection in vulnerable populations.
• Intranasal live attenuated vaccines and inactivated parenteral vaccines are common influenza A prophylaxis options.

Purpose of the Study:

• To compare the efficacy and immunogenicity of live attenuated intranasal influenza A vaccines versus inactivated parenteral influenza A vaccines.
• To assess vaccine effects on symptomatology and immune responses in children and young adults with cystic fibrosis.

Main Methods:

• A double-blind clinical trial involving 55 children and young adults with cystic fibrosis.
• Administration of bivalent, live attenuated intranasal influenza A vaccine or inactivated, parenterally administered influenza A vaccine.
• Monitoring of symptomatology and assessment of serum and nasal secretion immune responses (IgA, IgG).

Main Results:

• No significant difference in symptomatology was observed between the live intranasal vaccine group and the placebo group.
• Serum immune responses were generally lower with live vaccines compared to inactivated vaccines, especially in adults.
• Minimal IgA response was detected in nasal secretions for both vaccine groups.
• A common IgG response in nasal secretions was observed with both live intranasal and inactivated parenteral vaccines.

Conclusions:

• Live attenuated intranasal influenza vaccines did not alter symptomatology in cystic fibrosis patients compared to placebo.
• While both vaccine types induced IgG nasal secretions, inactivated vaccines elicited a more robust serum immune response.
• Further research may be needed to optimize intranasal vaccine strategies for this population.